NCT07341191 2026-02-12
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Phase 2 Not yet recruiting
Clinical Trials
4 trialsNCT07261163 2025-12-03
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT06427213 2024-05-23
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06255704 2024-02-13
Z+RCHOP/RDHAP
Shanxi Province Cancer Hospital
Phase 2 Not yet recruiting